The GlioME team published a new article in Oncotarget journal: EB1-dependent long survival of glioblastoma-grafted mice with the oral tubulin-binder BAL101553 is associated with inhibition of tumor angiogenesis.

Our study shows that a treatment with the microtubule-destabilizing agent BAL101553 counteracts tumor angiogenesis by acting on glioblastoma stem-like cells, in an EB1-dependent manner. This work provides new insights into the therapeutic targeting of cancer stem-like cells.